検索結果 17 件
| JaLCDOI | 10.18926/AMO/68355 |
|---|---|
| フルテキストURL | 79_1_021.pdf |
| 著者 | Yamamoto, Yasuhiro| Haraguchi, Takafumi| Matsuda, Kaori| Okazaki, Yoshio| Kimoto, Shin| Tanji, Nozomu| Matsumoto, Atsushi| Kobayashi, Yasuyuki| Mimura, Hidefumi| Hiraki, Takao| |
| 抄録 | We developed a machine learning model for predicting prostate cancer (PCa) grades using radiomic features of magnetic resonance imaging. 112 patients diagnosed with PCa based on prostate biopsy between January 2014 and December 2021 were evaluated. Logistic regression was used to construct two prediction models, one using radiomic features and prostate-specific antigen (PSA) values (Radiomics model) and the other Prostate Imaging-Reporting and Data System (PI-RADS) scores and PSA values (PI-RADS model), to differentiate high-grade (Gleason score [GS] ≥ 8) from intermediate or low-grade (GS < 8) PCa. Five imaging features were selected for the Radiomics model using the Gini coefficient. Model performance was evaluated using AUC, sensitivity, and specificity. The models were compared by leave-one-out cross-validation with Ridge regularization. Furthermore, the Radiomics model was evaluated using the holdout method and represented by a nomogram. The AUC of the Radiomics and PI-RADS models differed significantly (0.799, 95% CI: 0.712-0.869; and 0.710, 95% CI: 0.617-0.792, respectively). Using holdout method, the Radiomics model yielded AUC of 0.778 (95% CI: 0.552-0.925), sensitivity of 0.769, and specificity of 0.778. It outperformed the PI-RADS model and could be useful in predicting PCa grades, potentially aiding in determining appropriate treatment approaches in PCa patients. |
| キーワード | prostate cancer machine learning prostate Imaging-Reporting and Data System radiomics Gleason score |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2025-02 |
| 巻 | 79巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 21 |
| 終了ページ | 30 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2025 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 40012156 |
| Web of Science KeyUT | 001440463800003 |
| レファレンス | Taitt HE: Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. Am J Mens Health (2018) 12: 1807-1823.| Rawla P: Epidemiology of Prostate Cancer. World J Oncol (2019) 10: 63-89.| Gong L, Xu M, Fang M, Zou J, Yang S, Yu X, Xu D, Zhou L, Li H, He B, Wang Y, Fang X, Dong D and Tian J: Noninvasive Prediction of High-Grade Prostate Cancer via Biparametric MRI Radiomics. J Magn Reson Imaging (2020) 52: 1102-1109.| Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T and Klein EA: A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol (2016) 69: 428-435.| Carroll PH and Mohler JL: NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection. J Natl Compr Canc Netw (2018) 16: 620-623.| Miyake H, Sakai I, Inoue TA, Hara I and Fujisawa M: The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men. Urol Int (2006) 77: 122-126.| Hassan O, Han M, Zhou A, Paulk A, Sun Y, Al-Harbi A, Alrajjal A, Baptista Dos Santos F and Epstein JI: Incidence of Extraprostatic Extension at Radical Prostatectomy with Pure Gleason Score 3+3=6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed “Not Cancer” and for Selection Criteria for Active Surveillance. J Urol (2018) 199: 1482-1487.| Albers LF, Korving JC, van Elzakker EPM and Roshani H: Osteomyelitis of the Pubic Symphysis After Transrectal Biopsies of the Prostate. Urology (2018) 121: 29-32.| van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J, van den Hout H, van der Lelij H, van Oort I, Klaver S, Debruyne F, Sedelaar M, Hannink G, Rovers M, Hulsbergen-van de Kaa C and Barentsz JO: Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. Eur Urol (2019) 75: 570-578.| Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, Weidner W and Loeb S: Complications After Systematic, Random, and Image-guided Prostate Biopsy. Eur Urol (2017) 71: 353-365.| Rajkomar A, Dean J and Kohane I: Machine Learning in Medicine. N Engl J Med (2019) 380: 1347-1358.| Cuocolo R, Cipullo MB, Stanzione A, Ugga L, Romeo V, Radice L, Brunetti A and Imbriaco M: Machine learning applications in prostate cancer magnetic resonance imaging. Eur Radiol Exp (2019) 3: 35.| Sun Y, Reynolds HM, Parameswaran B, Wraith D, Finnegan ME, Williams S and Haworth A: Multiparametric MRI and radiomics in prostate cancer: a review. Australas Phys Eng Sci Med (2019) 42: 3-25.| Schelb P, Kohl S, Radtke JP, Wiesenfarth M, Kickingereder P, Bickelhaupt S, Kuder TA, Stenzinger A, Hohenfellner M, Schlemmer HP, Maier-Hein KH and Bonekamp D: Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment. Radiology (2019) 293: 607-617.| Antonelli M, Johnston EW, Dikaios N, Cheung KK, Sidhu HS, Appayya MB, Giganti F, Simmons LAM, Freeman A, Allen C, Ahmed HU, Atkinson D, Ourselin S and Punwani S: Machine learning classifiers can predict Gleason pattern 4 prostate cancer with greater accuracy than experienced radiologists. Eur Radiol (2019) 29: 4754-4764.| Bleker J, Kwee TC, Dierckx RAJO, de Jong IJ, Huisman H and Yakar D: Multiparametric MRI and auto-fixed volume of interest-based radiomics signature for clinically significant peripheral zone prostate cancer. Eur Radiol (2020) 30: 1313-1324.| Bagher-Ebadian H, Janic B, Liu C, Pantelic M, Hearshen D, Elshaikh M, Movsas B, Chetty IJ and Wen N: Detection of Dominant Intra-prostatic Lesions in Patients With Prostate Cancer Using an Artificial Neural Network and MR Multi-modal Radiomics Analysis. Front Oncol (2019) 9: 1313.| Chaddad A, Kucharczyk M and Niazi T: Multimodal radiomic features for the predicting gleason score of prostate cancer. Cancers (Basel) (2018) 10: 249.| Monti S, Brancato V, Costanzo GD, Basso L, Puglia M, Ragozzino A, Salvatore M and Cavaliere C: Multiparametric MRI for prostate cancer detection: New insights into the combined use of a radiomic approach with advanced acquisition protocol. Cancers (2020) 12: 390.| Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, Thoeny HC, Verma S, Barentsz J and Weinreb JC: Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol (2019) 76: 340-351.| Demšar J, Curk T, Erjavec A, Gorup Č, Hočevar T, Milutinovič M, Možina M, Polajnar M, Toplak M, Starič A and Štajdohar M: Orange: data mining toolbox in Python. J Mach Learn Res (2013) 14: 2349-2353.| Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, JLH van Leenders G, Liew M, Linares Espinos E, Oldenburg J, van Oort IM, Oprea-Lager DE, Ploussard G, Roberts MJ, Rouvière O, Schoots IG, Schouten N, Smith EJ, Stranne J, Wiegel T, Willemse PM and Cornford P: EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol (2024) 29: 02306-6.| Khalvati F, Wong A and Haider MA: Automated prostate cancer detection via comprehensive multi-parametric magnetic resonance imaging texture feature models. BMC Med Imaging (2015) 15: 27.| Kwak JT, Xu S, Wood BJ, Turkbey B, Choyke PL, Pinto PA, Wang S and Summers RM: Automated prostate cancer detection using T2-weighted and high-b-value diffusion-weighted magnetic resonance imaging. Med Phys (2015) 42: 2368-2378.| Zhao C, Gao G, Fang D, Li F, Yang X, Wang H, He Q and Wang X: The efficiency of multiparametric magnetic resonance imaging (mpMRI) using PI-RADS Version 2 in the diagnosis of clinically significant prostate cancer. Clin Imaging (2016) 40: 885-888.| Chen T, Li M, Gu Y, Zhang Y, Yang S, Wei C, Wu J, Li X, Zhao W and Shen J: Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2. J Magn Reson Imaging (2019) 49: 875-884.| Hegde JV, Mulkern RV, Panych LP, Fennessy FM, Fedorov A, Maier SE and Tempany CM: Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging (2013) 37: 1035-1054.| Donati OF, Mazaheri Y, Afaq A, Vargas HA, Zheng J, Moskowitz CS, Hricak H and Akin O: Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient. Radiology (2014) 271: 143-152.| Chen T, Zhang Z, Tan S, Zhang Y, Wei C, Wang S, Zhao W, Qian X, Zhou Z, Shen J, Dai Y and Hu J: MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI. Front Oncol (2022) 11: 792456.| Zhang L, Zhe X, Tang M, Zhang J, Ren J, Zhang X and Li L: Predicting the Grade of Prostate Cancer Based on a Biparametric MRI Radiomics Signature. Contrast Media Mol Imaging (2021) 2021: 7830909.| Bagher-Ebadian H, Janic B, Liu C, Pantelic M, Hearshen D, Elshaikh M, Movsas B, Chetty IJ and Wen N: Detection of Dominant Intra-prostatic Lesions in Patients With Prostate Cancer Using an Artificial Neural Network and MR Multi-modal Radiomics Analysis. Front Oncol (2019) 9: 1313.| van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, Beets-Tan RGH, Fillion-Robin JC, Pieper S and Aerts HJWL: Computational Radiomics System to Decode the Radiographic Phenotype. Cancer Res (2017) 77: e104-e107.| |
| JaLCDOI | 10.18926/AMO/66913 |
|---|---|
| フルテキストURL | 78_2_107.pdf |
| 著者 | Han, Dongxiang| Du, Jianxiu| Wang, Wei| Wang, Cui| |
| 抄録 | Vertical transmission of hepatitis B virus (HBV), especially in Asia, is a key target in the global elimination of HBV. This study assessed the effects of tenofovir disoproxil fumarate (TDF) in pregnant women for mother-to-infant transmission of HBV. A total of 122 pregnant women at our hospital met the inclusion criteria for high HBV DNA viral loads. They were randomly divided into TDF-treatment (n=70) and placebo (n=52) groups. Maternal liver function and serum HBV DNA load were tested before and after treatment. Clinical and laboratory data of infants were assayed at delivery and 7-months post-partum visit and compared between the two groups. There was no difference in clinical characteristics of participants between the two groups. There were no significant differences in liver function markers, including alanine aminotransferase, total bilirubin, blood creatinine, and blood urea nitrogen levels before and after TDF treatment. The serum HBV DNA viral load of the TDF-treated group became significantly lower than those of the control group and their own pre-medication levels. Infants showed no significant difference in body growth, including weight, height, head size, and five-min Apgar score. At 7 months after birth, 94.29% of infants in the TDF group and 86.54% of control-group infants had protective HBsAb levels ≥ 10 mIU/ml (p>0.05). The HBV infection rate of infants in the TDF-treated group was lower than that in the non-treated group. In high-HBV-DNA-load pregnant women, TDF administered from 28 weeks gestational age to delivery was associated with a lower risk of mother-to-infant transmission of HBV. |
| キーワード | mother-to-infant transmission tenofovir disoproxil fumarate hepatitis B virus |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2024-04 |
| 巻 | 78巻 |
| 号 | 2号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 107 |
| 終了ページ | 113 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2024 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 38688828 |
| Web of Science KeyUT | 001229151800002 |
| JaLCDOI | 10.18926/AMO/66912 |
|---|---|
| フルテキストURL | 78_2_095.pdf |
| 著者 | Itano, Junko| Kiura, Katsuyuki| Maeda, Yoshinobu| Miyahara, Nobuaki| |
| 抄録 | The lungs are very complex organs, and the respiratory system performs the dual roles of repairing tissue while protecting against infection from various environmental stimuli. Persistent external irritation disrupts the immune responses of tissues and cells in the respiratory system, ultimately leading to respiratory disease. Neuropeptide Y (NPY) is a 36-amino-acid polypeptide and a neurotransmitter that regulates homeostasis. The NPY receptor is a seven-transmembrane-domain G-protein-coupled receptor with six subtypes (Y1, Y2, Y3, Y4, Y5, and Y6). Of these receptors, Y1, Y2, Y4, and Y5 are functional in humans, and Y1 plays important roles in the immune responses of many organs, including the respiratory system. NPY and the Y1 receptor have critical roles in the pathogenesis of asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The effects of NPY on the airway immune response and pathogenesis differ among respiratory diseases. This review focuses on the involvement of NPY in the airway immune response and pathogenesis of various respiratory diseases. |
| キーワード | neuropeptide y Y1 receptor airway immune response bronchial epithelial cells respiratory disease |
| Amo Type | Review |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2024-04 |
| 巻 | 78巻 |
| 号 | 2号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 95 |
| 終了ページ | 106 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2024 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 38688827 |
| Web of Science KeyUT | 001229151800001 |
| JaLCDOI | 10.18926/AMO/65489 |
|---|---|
| フルテキストURL | 77_3_243.pdf |
| 著者 | Shibata, Yusuke| Eguchi, Jun| Wada, Jun| |
| 抄録 | Brown adipose tissue (BAT) plays a critical role in metabolic homeostasis. BAT dysfunction is associated with the development of obesity through an imbalance between energy expenditure and energy intake. The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is the master regulator of adipogenesis. However, the roles of PPARγ and thiazolidinediones (TZDs) in the regulation of BAT metabolism remain unclear. TZDs, which are selective PPARγ activators, improve systemic insulin resistance in animals and humans. In the present study, we generated brown adipocyte-specific PPARγ-deficient mice (BATγKO) to examine the in vivo roles of PPARγ and TZDs in BAT metabolism. In electron microscopic examinations, brown adipocyte-specific PPARγ deletion promoted severe whitening of brown fat and morphological alteration of mitochondria. Brown adipocyte-specific PPARγ deletion also reduced mRNA expression of BAT-selective genes. Although there was no difference in energy expenditure between control and BATγKO mice in calorimetry, norepinephrine-induced thermogenesis was impaired in BATγKO mice. Moreover, pioglitazone treatment improved diet-induced insulin resistance in the control mice but not in the BATγKO mice. These findings suggest that BAT PPARγ is necessary for the maintenance of brown adipocyte function and for the insulin-sensitizing action of TZDs. |
| キーワード | PPARγ brown adipose tissue thiazolidinediones |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2023-06 |
| 巻 | 77巻 |
| 号 | 3号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 243 |
| 終了ページ | 254 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2023 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 37357625 |
| Web of Science KeyUT | 001026279600002 |
| JaLCDOI | 10.18926/AMO/64119 |
|---|---|
| フルテキストURL | 76_6_689.pdf |
| 著者 | Yamanouchi, Kosho| Kuba, Sayaka| Matsumoto, Megumi| Yano, Hiroshi| Morita, Michi| Sakimura, Chika| Otsubo, Ryota| Hidaka, Masaaki| Nagayasu, Takeshi| Eguchi, Susumu| |
| 抄録 | Taxanes are key drugs for patients with breast cancer. A major adverse effect of taxanes is peripheral neuropathy (PN). To investigate the ability of compression therapy using sleeves and stockings to prevent PN due to the taxane docetaxel, we conducted a single-center historical control trial. Patients receiving docetaxel at 75 mg/m2 every 3 weeks for 4 cycles as first-line chemotherapy for breast cancer were eligible. PN was evaluated using the common terminology criteria for adverse events version 4.0. The primary endpoint was the incidence of allgrade PN until 3 weeks after the fourth docetaxel administration. We evaluated 26 patients in the intervention group and compared their data to those collected retrospectively from 52 patients treated with docetaxel without compression. Neither the incidence of all-grade PN until 3 weeks after the fourth docetaxel administration (63.5% in the control group vs. 76.9% in the intervention group, p=0.31) nor that of PN grade ≥ 2 (13.5% vs. 15.4%, p=0.99) differed between the groups. In this study, the efficacy of compression therapy using sleeves and stockings to prevent PN induced by docetaxel was not demonstrated. Further clinical studies including medications or intervention are needed to reduce the incidence and severity of PN induced by chemotherapy. |
| キーワード | breast cancer docetaxel neuropathy compression |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2022-12 |
| 巻 | 76巻 |
| 号 | 6号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 689 |
| 終了ページ | 694 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2022 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 36549771 |
| Web of Science KeyUT | 000905195100009 |
| JaLCDOI | 10.18926/AMO/64116 |
|---|---|
| フルテキストURL | 76_6_661.pdf |
| 著者 | Abe, Yuko| Taira, Naruto| Kashiwabara, Kosuke| Tsurutani, Junji| Kitada, Masahiro| Takahashi, Masato| Kato, Hiroaki| Kikawa, Yuichiro| Sakata, Eiko| Naito, Yoichi| Hasegawa, Yoshie| Saito, Tsuyoshi| Iwasa, Tsutomu| Takashima, Tsutomu| Aihara, Tomohiko| Mukai, Hirofumi| Hara, Fumikata| Shien, Tadahiko| Doihara, Hiroyoshi| Toyooka, Shinichi| |
| 抄録 | Chemotherapy-induced peripheral neuropathy (CIPN) is an important clinical challenge that threatens patients’ quality of life. This sub-study of the ABROAD trial investigated the influence of single nucleotide polymorphisms (SNPs) on CIPN, using genotype data from a randomized study to determine the optimal dose of a 3-week-cycle regimen of nab-paclitaxel (q3w nab-PTX) in patients with metastatic breast cancer (MBC). Patients with HER2-negative MBC were randomly assigned to three doses of q3w nab-PTX (SD: 260 mg/m2 vs. MD: 220 mg/m2 vs. LD: 180 mg/m2). Five SNPs (EPHA4-rs17348202, EPHA5-rs7349683, EPHA6-rs301927, LIMK2-rs5749248, and XKR4-rs4737264) were analyzed based on the results of a previous genome-wide association study. Per-allele SNP associations were assessed by a Cox regression to model the cumulative dose of nab-PTX up to the onset of severe or worsening sensory neuropathy. A total of 141 patients were enrolled in the parent study; 91(65%) were included in this sub-study. Worsening of CIPN was significantly greater in the cases with XKR4 AC compared to those with a homozygote AA (HR 1.86, 95%CI: 1.00001−3.46, p=0.049). There was no significant correlation of CIPN with any other SNP. A multivariate analysis showed that the cumulative dose of nab-PTX was most strongly correlated with CIPN (p<0.01). |
| キーワード | metastatic breast cancer taxane-induced peripheral neuropathy chemotherapy-induced peripheral neuropathy nab-paclitaxel single nucleotide polymorphism |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2022-12 |
| 巻 | 76巻 |
| 号 | 6号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 661 |
| 終了ページ | 671 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2022 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 36549768 |
| Web of Science KeyUT | 000905195100006 |
| JaLCDOI | 10.18926/AMO/64044 |
|---|---|
| フルテキストURL | 76_5_609.pdf |
| 著者 | Matsumoto, Ken| Fujishita, Keigo| Matsuda, Masayuki| Oka, Satoshi| Fujisawa, Yuka| Imai, Toshi| Machida, Takuya| |
| 抄録 | A 69-year-old Japanese man with acute leukemia received post-transplant cyclophosphamide-based haploidentical stem cell transplantation (PTCY-haplo-SCT) but was readmitted with dyspnea and ground-glass-opacities of the lungs. Bronchoscopy showed inflammatory changes with no signs of infection. He received steroids but required intubation as his condition deteriorated. In addition to antithymocyte globulin and cyclophosphamide, we administered ruxolitinib but failed to save him. Autopsy findings revealed fibrotic nonspecific interstitial pneumonia (NSIP) without evidence of organizing pneumonia or infection. Thus, we diagnosed idiopathic pneumonia syndrome (IPS). As far as our knowledge, this is the first case of IPS with NSIP histology after PTCY-haplo-SCT. |
| キーワード | idiopathic pneumonia syndrome ruxolitinib post-transplant cyclophosphamide-based haploidentical stem cell transplantation nonspecific interstitial pneumonia |
| Amo Type | Case Report |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2022-10 |
| 巻 | 76巻 |
| 号 | 5号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 609 |
| 終了ページ | 615 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2022 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 36352810 |
| Web of Science KeyUT | 000884907100016 |
| JaLCDOI | 10.18926/AMO/64039 |
|---|---|
| フルテキストURL | 76_5_577.pdf |
| 著者 | Okutani, Yuki| Fujita, Hiroshi| Harada, Hideto| Kataoka, Masanao| Murotani, Yoshiki| Shimizu, Yu| |
| 抄録 | The prevalence of preoperative deep vein thrombosis (DVT) has been reported to be relatively high in patients undergoing total hip arthroplasty. We investigated the prevalence of DVT, the association between hip function and preoperative DVT, and the effect of a history of surgery in patients who underwent primary total hip arthroplasty. We retrospectively analyzed the cases of the patients who underwent primary total hip arthroplasty between April 2013 and February 2020 at our institution. We evaluated the prevalence of preoperative DVT based on the results of the patients’ ultrasound screening. We performed univariate and multivariate analyses to investigate the association between the incidence of DVT and patient factors including age, sex, hip function, medical histories, and American Society of Anesthesiologists Physical Status classification. We analyzed 451 patients (494 hips). The prevalence of DVT was 14.2% (64 patients). The multivariate analysis demonstrated that increased age was an independent significant risk factor for DVT. The prevalence of preoperative DVT was relatively high among patients who underwent primary total hip arthroplasty. Preoperative DVT tended to be more prevalent in older patients. Hip function was not associated with the incidence of DVT. |
| キーワード | total hip arthroplasty deep vein thrombosis hip function ultrasound screening |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2022-10 |
| 巻 | 76巻 |
| 号 | 5号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 577 |
| 終了ページ | 584 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2022 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 36352805 |
| Web of Science KeyUT | 000884907100011 |
| JaLCDOI | 10.18926/AMO/64025 |
|---|---|
| フルテキストURL | 76_5_503.pdf |
| 著者 | Ogawa, Hirohito| Honda, Tomoyuki| |
| 抄録 | Eukaryotic genomes contain numerous copies of endogenous viral elements (EVEs), most of which are considered endogenous retrovirus (ERV) sequences. Over the past decade, non-retroviral endogenous viral elements (nrEVEs) derived from ancient RNA viruses have been discovered. Several functions have been proposed for these elements, including antiviral defense. This review summarizes the current understanding of nrEVEs derived from RNA viruses, particularly endogenous bornavirus-like elements (EBLs) and endogenous filovirus-like elements (EFLs). EBLs are one of the most extensively studied nrEVEs. The EBL derived from bornavirus nucleoprotein (EBLN) is thought to function as a non-coding RNA or protein that regulates host gene expression or inhibits virus propagation. Ebolavirus and marburgvirus, which are filoviruses, induce severe hemorrhagic fever in humans and nonhuman primates. Although the ecology of filoviruses remains unclear, bats are believed to be potential reservoirs. Based on the knowledge from EBLs, it is postulated that EFLs in the bat genome help to maintain the balance between filovirus infection and the bat’s defense system, which may partially explain why bats act as potential reservoirs. Further research into the functions of nrEVEs could reveal novel antiviral systems and inspire novel antiviral approaches. |
| キーワード | EVE nrEVE bornavirus filovirus antiviral |
| Amo Type | Review |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2022-10 |
| 巻 | 76巻 |
| 号 | 5号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 503 |
| 終了ページ | 510 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2022 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 36352796 |
| Web of Science KeyUT | 000884907100002 |
| JaLCDOI | 10.18926/AMO/64024 |
|---|---|
| フルテキストURL | 76_5_489.pdf |
| 著者 | Matsumoto, Yuji| Ichikawa, Tomotsugu| Kurozumi, Kazuhiko| Date, Isao| |
| 抄録 | Glioblastoma (GBM) is a fatal primary malignant brain tumor in adults. Despite decades of research, the prognosis for GBM patients is still disappointing. One major reason for the intense therapeutic resistance of GBM is inter- and intra-tumor heterogeneity. GBM-intrinsic transcriptional profiling has suggested the presence of at least three subtypes of GBM: the proneural, classic, and mesenchymal subtypes. The mesenchymal subtype is the most aggressive, and patients with the mesenchymal subtype of primary and recurrent tumors tend to have a worse prognosis compared with patients with the other subtypes. Furthermore, GBM can shift from other subtypes to the mesenchymal subtype over the course of disease progression or recurrence. This phenotypic transition is driven by diverse tumor-intrinsic molecular mechanisms or microenvironmental factors. Thus, better understanding of the plastic nature of mesenchymal transition in GBM is pivotal to developing new therapeutic strategies. In this review, we provide a comprehensive overview of the current understanding of the elements involved in the mesenchymal transition of GBM and discuss future perspectives. |
| キーワード | glioma glioblastoma mesenchymal subtype mesenchymal transition heterogeneity |
| Amo Type | Review |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2022-10 |
| 巻 | 76巻 |
| 号 | 5号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 489 |
| 終了ページ | 502 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2022 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 36352795 |
| Web of Science KeyUT | 000884907100001 |
| JaLCDOI | 10.18926/AMO/63908 |
|---|---|
| フルテキストURL | 76_4_479.pdf |
| 著者 | Ogawa, Chikako| Hirasawa, Akira| Sogawa, Reimi| Hasuoka, Kayoko| Tomida, Shuta| Futagawa, Mashu| Urakawa, Yusaku| Kochi, Mariko| Yamamoto, Hideki| Nakamura, Keiichiro| Masuyama, Hisashi| |
| 抄録 | A hereditary breast and ovarian cancer (HBOC) pedigree was detected via liquid biopsy, and cancer prevention was initiated for the patient’s daughter, after receiving a definitive result from BRCA genetic testing. A 48-yearold woman with ovarian cancer was administered precision medicine, which used cell-free DNA from plasma. The results revealed a pathogenic variant of BRCA1 as a presumed germline pathogenic mutation. We confirmed the germline pathological variant BRCA1 c.81-1G> A and suggested treatment with a PARP inhibitor. One of her three children had the variant, was diagnosed as an unaffected pathogenic variant carrier, and was advised to initiate surveillance. |
| キーワード | hereditary breast and ovarian cancer (HBOC) BRCA 1 presumed germline pathogenic variants (PGPV) germline findings cancer precision medicine |
| Amo Type | Case Report |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2022-08 |
| 巻 | 76巻 |
| 号 | 4号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 479 |
| 終了ページ | 483 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2022 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 36123164 |
| Web of Science KeyUT | 000882167300012 |
| JaLCDOI | 10.18926/AMO/63893 |
|---|---|
| フルテキストURL | 76_4_391.pdf |
| 著者 | Habu, Hiroshi| Mitsuhashi, Toshiharu| Tokinobu, Akiko| Yorifuji, Takashi| Takao, Soshi| |
| 抄録 | Tanden breathing, an ancient health technique, involves expiratory abdominal pressure breathing is practiced in Japan. In this study we examined the ability of Tanden breathing to relieve constipation. The study was designed as a stratified-block randomized controlled trial enrolling 20 participants. Nineteen were female and one was male, none were elderly. During the 6-week intervention period, the participants performed video-guided Tanden breathing about 10 min once day. We evaluated constipation using the Constipation Assessment Scale (CAS). There were significant differences in the mean CAS score between time points (baseline, 3 weeks after baseline, 6 weeks after baseline), groups (intervention and control), and their interaction (time×group) using repeated-measures analysis of variance. The control group showed no change in the mean CAS score; the mean CAS scores of the intervention group changed from 7.2 at baseline to 3.9 at 3 weeks and 3.1 at 6 weeks after baseline. A regression analysis of the difference in the mean CAS between baseline and 6 weeks later showed that the CAS of the intervention group was 4.3 points lower than that of the control group (95% confidence interval, 2.5-6.1). The results suggested that Tanden breathing is effective in relieving constipation among young women. |
| キーワード | Tanden breathing Dantian breathing exercises constipation mind−body therapy |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2022-08 |
| 巻 | 76巻 |
| 号 | 4号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 391 |
| 終了ページ | 398 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2022 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 36123153 |
| Web of Science KeyUT | 000882167300001 |
| JaLCDOI | 10.18926/AMO/63213 |
|---|---|
| フルテキストURL | 76_1_63.pdf |
| 著者 | Zhang, Bei| Pei, Zhixin| Wang, Hongxia| Wu, Huimin| Wang, Junjie| Bai, Junjun| Song, Qinglin| |
| 抄録 | We analyzed the treatment effects of chidamide and decitabine in combination with a HAG (homoharringtonine, cytarabine, G-CSF) priming regimen (CDHAG) in acute myeloid leukemia (AML) patients with TP53 mutation. Seven TP53 mutated AML patients were treated with CDHAG. The treatment effects were assessed using hemogram detection and bone marrow aspirate. The possible side effects were evaluated based on both hematological and non-hematological toxicity. Four of the seven patients were classified as having achieved complete remission after CDHAG treatment; one patient was considered to have achieved partial remission, and the remaining two patients were considered in non-remission. The overall response rate (ORR) to CDHAG was 71.4%. Regarding the side effects, the hematological toxicity level of the seven patients ranged from level III to level IV, and infections that occurred at lung, blood, and skin were recorded. Nausea, vomiting, liver injury, and kidney injury were also detected. However, all side effects were attenuated by proper management. The CDHAG regimen clearly improved the ORR (71.4%) of TP53-mutated AML patients, with no severe side effects. |
| キーワード | acute myeloid leukemia chidamide decitabine HAG TP53 mutation |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2022-02 |
| 巻 | 76巻 |
| 号 | 1号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 63 |
| 終了ページ | 70 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2022 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 35237000 |
| Web of Science KeyUT | 000762812700009 |
| JaLCDOI | 10.18926/AMO/56930 |
|---|---|
| フルテキストURL | 73_4_285.pdf |
| 著者 | Otani, Yoshihiro| Ichikawa, Tomotsugu| Kurozumi, Kazuhiko| Date, Isao| |
| 抄録 | Gliomas are characterized as highly diffuse infiltrating tumors, and currently available treatments such as surgery, radiation and chemotherapy are unfeasible or show limited efficacy against these tumors. Recent genetic and epigenetic analyses of glioma have revealed increasing evidence of the role of driver genetic alterations in glioma development and led to the identification of prognostic factors. Despite these findings, the survival rates of glioma patients remain low, and alternative treatments and novel targets are needed. Recent studies identified neural stem cells as the possible origin of gliomas, and some evidence has revealed shared functions and mechanisms between glioma cells and neurons, also supporting their similarity. The cytoskeleton plays important roles in the migration of normal cells as well as cancer cells. Recent reports have described a role for microtubules, a component of the cytoskeleton, in glioma invasion. Notably, several factors that regulate microtubule functions, such as microtubule-associated proteins, plus-end tracking proteins, or motor proteins, are upregulated in glioma tissues compared with normal tissue, and upregulation of these factors is associated with high invasiveness of glioma cells. In this review, we describe the mechanism of microtubules in glioma invasion and discuss the possibility of microtubule-targeted therapy to inhibit glioma invasion. |
| キーワード | glioma cytoskeletons invasion microtubules |
| Amo Type | Review |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2019-08 |
| 巻 | 73巻 |
| 号 | 4号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 285 |
| 終了ページ | 297 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2019 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 31439951 |
| JaLCDOI | 10.18926/AMO/56868 |
|---|---|
| フルテキストURL | 73_3_247.pdf |
| 著者 | Yoshio, Kotaro| Wakita, Akihisa| Mitsuhashi, Toshiharu| Kitayama, Takahiro| Hisazumi, Kento| Inoue, Daisaku| Tajiri, Nobuhisa| Shiode, Tsuyoki| Akaki, Shiro| Kanazawa, Susumu| |
| 抄録 | We investigated the feasibility of simultaneous integrated boost (SIB) volumetric modulated arc therapy (VMAT) using elective nodal irradiation (ENI) for middle or lower esophageal cancer and compared it with three-dimensional conformal radiotherapy (3D-CRT). The study included 15 patients. The prescribed doses included a standard dose (50.4 Gy) and a high dose (60 Gy) for the planning target volume (PTV) of the involved lesions. The objective of the whole lung volume receiving ≥ 20 Gy (V20Gy) was < 30%, and the mean lung dose (MLD) was < 20 Gy. The volumes of the lung receiving 5 Gy (V5Gy) and the heart receiving 30-50 Gy (V30-50Gy) were kept as low as reasonably achievable. As a result, SIB-VMAT showed superior dose conformity for the PTV (p<0.001). Although the lung V5Gy was significantly increased (p<0.001), the V20Gy and MLD showed no significant increase. The heart V30-50Gy showed a > 20% reduction in the mean against 3D-CRTs. Our results demonstrate the feasibility of SIB-VMAT for the treatment of middle or lower esophageal cancer with ENI. Although attention should be paid to the low-dose area of the lungs, SIB-VMAT would be a promising treatment option with improved outcomes for esophageal cancer. |
| キーワード | esophageal cancer middle and lower thoracic volumetric modulated arc therapy, 3D-CRT elective nodal irradiation |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2019-06 |
| 巻 | 73巻 |
| 号 | 3号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 247 |
| 終了ページ | 257 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2019 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 31235973 |
| 著者 | 長尾 一孝| |
|---|---|
| 発行日 | 1994-08 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 106巻 |
| 号 | 7-8号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 金澤 右| |
|---|---|
| 発行日 | 2005-01-31 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 116巻 |
| 号 | 3号 |
| 資料タイプ | 学術雑誌論文 |